36.84

3.59% -1.37

Harmony Biosciences Holdings Inc (HRMY)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt HRMY? Forum Prognose

Schlusskurs vom Vortag:

$38.21

Offen:

$38.44

24-Stunden-Volumen:

668.82K

Relative Volume:

0.81

Marktkapitalisierung:

$2.13B

Einnahmen:

$899.11M

Nettoeinkommen (Verlust:

$145.62M

KGV:

14.84

EPS:

2.4829

Netto-Cashflow:

$322.54M

1W Leistung:

-1.13%

1M Leistung:

+3.83%

6M Leistung:

-4.44%

1J Leistung:

+7.31%

1-Tages-Spanne:

$36.17

$38.50

1-Wochen-Bereich:

$36.17

$38.89

52-Wochen-Spanne:

$25.52

$40.87

Harmony Biosciences Holdings Inc Stock (HRMY) Company Profile

Firmenname

Harmony Biosciences Holdings Inc

Sektor

Healthcare (1096)

Branche

Biotechnology (616)

Telefon

(484) 539-9800

Adresse

630 W GERMANTOWN PIKE, PLYMOUTH MEETING

Mitarbeiter

293

Twitter

Nächster Verdiensttermin

2026-08-04

Neueste SEC-Einreichungen

HRMY's Discussions on Twitter

Compare HRMY vs VRTX, REGN, ARGX, ALNY, RVMD

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
HRMY Harmony Biosciences Holdings Inc	36.84	2.13B	899.11M	145.62M	322.54M	2.4829
VRTX Vertex Pharmaceuticals Inc	485.39	123.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	664.52	69.67B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	877.62	54.58B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	298.76	39.89B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	186.88	39.73B	742.00K	-1.37B	-1.07B	-7.0731

Harmony Biosciences Holdings Inc Stock (HRMY) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-02-23	Herabstufung	Deutsche Bank	Buy → Hold
2026-02-23	Herabstufung	Truist	Buy → Hold
2026-02-11	Fortgesetzt	UBS	Neutral
2025-07-21	Eingeleitet	Truist	Buy
2025-07-10	Fortgesetzt	Goldman	Neutral
2025-06-02	Fortgesetzt	Oppenheimer	Outperform
2025-02-11	Eingeleitet	Deutsche Bank	Buy
2024-12-17	Eingeleitet	H.C. Wainwright	Buy
2024-10-10	Fortgesetzt	Raymond James	Outperform
2024-09-10	Eingeleitet	UBS	Buy
2024-06-21	Eingeleitet	Citigroup	Buy
2024-01-02	Herabstufung	BofA Securities	Neutral → Underperform
2023-09-25	Herabstufung	Goldman	Neutral → Sell
2023-09-07	Eingeleitet	Berenberg	Buy
2023-04-20	Eingeleitet	BofA Securities	Neutral
2022-10-14	Hochstufung	Janney	Neutral → Buy
2022-10-14	Hochstufung	Jefferies	Hold → Buy
2022-08-03	Herabstufung	Jefferies	Buy → Hold
2022-07-13	Herabstufung	Goldman	Buy → Neutral
2022-07-07	Eingeleitet	Mizuho	Buy
2022-04-14	Eingeleitet	Cantor Fitzgerald	Overweight
2021-12-01	Eingeleitet	Oppenheimer	Outperform
2021-11-04	Eingeleitet	Raymond James	Outperform
2021-09-23	Eingeleitet	Needham	Buy
2021-03-29	Hochstufung	Goldman	Neutral → Buy
2020-09-14	Eingeleitet	Goldman	Neutral
2020-09-14	Eingeleitet	Jefferies	Buy
2020-09-14	Eingeleitet	Piper Sandler	Overweight

Alle ansehen

Harmony Biosciences Holdings Inc Aktie (HRMY) Neueste Nachrichten

Jul 09, 2026

Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail

Jul 09, 2026

Enterprise value to EBITDA forward of Harmony Biosciences Holdings, Inc. – NASDAQ:HRMY - TradingView

Jul 09, 2026

Jul 08, 2026

Mizuho reiterates Harmony Biosciences stock rating on patent case - Investing.com

Jul 08, 2026

Mizuho Reiterates Outperform Rating on Harmony Biosciences Holdings Inc. (HRMY) - StreetInsider

Jul 08, 2026

Jul 07, 2026

HRMY growth trends beyond Wakix could shape its next growth phase - MSN

Jul 07, 2026

Jul 05, 2026

Price to sales forward of Harmony Biosciences Holdings, Inc. – NASDAQ:HRMY - TradingView

Jul 05, 2026

Jul 04, 2026

Harmony Biosciences holds steady as investors await the next catalyst. - ad-hoc-news.de

Jul 03, 2026

Top 5 US Stocks To Buy In July 2026 - Investing.com

Jul 03, 2026

Jul 02, 2026

25,000-share option exercise; affiliate sales reported — HRMY - Stock Titan

Jul 02, 2026

Jun 30, 2026

Form 144 HARMONY BIOSCIENCES HOLDINGS For: 30 June By Investing.com - Investing.com Nigeria

Jun 30, 2026

Sandip Kapadia reports sale activity (HRMY) via Form 144 totaling 50,000 - Stock Titan

Jun 30, 2026

HRMY Maintained by Deutsche Bank -- Price Target Raised to $36 - GuruFocus

Jun 30, 2026

Deutsche Bank Adjusts Price Target on Harmony Biosciences to $36 From $30, Maintains Hold Rating - marketscreener.com

Jun 30, 2026

Jun 29, 2026

Is HRMY Stock Worth Buying With Neutral Signals and Cheap Valuation? - TradingView

Jun 29, 2026

Harmony Biosciences Stock Outlook as Wakix Growth Meets Pipeline - Yahoo Finance

Jun 29, 2026

HRMY Growth Trends Beyond Wakix Could Shape Its Next Growth Phase - Zacks Investment Research

Jun 29, 2026

Jun 27, 2026

HRMY Stock On Track For Best Intraday Gains In 18 Months — What Did Mizuho Analysts Say? - Stocktwits

Jun 27, 2026

Form 144 HARMONY BIOSCIENCES HOLDINGS For: 26 June By Investing.com - Investing.com South Africa

Jun 27, 2026

Harmony Biosciences (HRMY) Surges 3.93% as Positive Momentum BuildsMACD Signal Stocks - dars.gov.et

Jun 27, 2026